The project partners are Meat & Livestock Australia, Tiba Biotech and the NSW Government.
While Australia remains FMD free, modelling has estimated an FMD outbreak could cost the economy up to $80 billion, having a catastrophic impact on trade, animal welfare and farm productivity.
MLA managing director Michael Crowley said while it was hoped an FMD vaccine would never be needed, the research represented a proactive approach to managing biosecurity risk.
“FMD is present in countries near to Australia and is front of mind for industry in terms of potential biosecurity risks,” Mr Crowley said.
“Vaccination may not necessarily be required in the event of a disease incursion, but this research demonstrates that the Australian industry is proactive and prepared.”
Researchers found that the new vaccine demonstrated strong, effective immune response and safety in preliminary trials in Germany. Vaccinated cattle did not contract FMD when exposed to the disease and, importantly, they did not shed the virus.
The new biodegradable vaccine uses mRNA to induce an immune response, rather than an actual virus. mRNA vaccines have been proven safe for animals and for consumers.
Following these trials, the vaccine must now undergo a rigorous evaluation process with the Australian Pesticides and Veterinary Medicines Authority before approval for use on livestock.
“Developing local capacity to produce vaccines against emergency animal diseases is a critical priority for the NSW Government, Australia’s livestock industries and our economy,” NSW Agriculture Minister Tara Moriarty said.
Australian-based Tiba co-founder Peter McGrath said the company was focused on working regulators to ensure vaccine safety and effectiveness.
“Australia is now at the forefront of livestock vaccine development, bringing with it the potential to develop manufacturing capacity, jobs and exports,” Mr McGrath said.
“Livestock mRNA vaccines offer a safe, efficient and effective approach to protecting animal health, benefiting both the agricultural industry and consumers.
“Unlike current mRNA technologies, our vaccines can be stored long-term at standard refrigeration temperatures and even at room temperature for at least one month. This is a critical advantage in livestock applications.”
The project is also conducting similar research to develop a vaccine for lumpy skin disease, which is also a significant exotic disease threat to Australia.
5°C